연구동향 분석
박사

약물 대사효소 및 수송체 유전형과 aspirin 병용투약이 clopidogrel의 약동학/약력학에 미치는 영향을 평가하기 위한 건강자원자 대상 임상시험

홍경섭 2016년

논문상세정보
인용/피인용
' 약물 대사효소 및 수송체 유전형과 aspirin 병용투약이 clopidogrel의 약동학/약력학에 미치는 영향을 평가하기 위한 건강자원자 대상 임상시험' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 약리학과 치료학
  • cyp2c19
  • mdr1
  • 아스피린
  • 클로피도그렐
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
57 0

0.0%

' 약물 대사효소 및 수송체 유전형과 aspirin 병용투약이 clopidogrel의 약동학/약력학에 미치는 영향을 평가하기 위한 건강자원자 대상 임상시험' 의 참고문헌

  • van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098-2104.
  • Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:1107-1112.
  • Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008;6:1439-1441.
  • Taubert D, von Beckerath N, Grimberg G, et al. Impact of Pglycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.
  • Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011:CD005158.
  • Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
  • Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317- 323.
  • Peace AJ, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost. 2008;6:2027-2034.
  • Ohmori T, Yano Y, Sakata A, et al. Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb Res. 2012;129:e36-40.
  • Oh J, Shin D, Lim KS, et al. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Clin Pharmacol Ther. 2014;95:608-616.
  • Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312-1319.
  • Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit. 2007;29:455-459.
  • Lake BG, Hopkins R, Chakraborty J, Bridges JW, Parke DV. The influence of some hepatic enzyme inducers and inhibitors on extrahepatic drug metabolism. Drug Metab Dispos. 1973;1:342-349.
  • Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther. 2010;35:697-703.
  • Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-242.
  • Jung KH, Chu K, Lee ST, et al. Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011;90:612-619.
  • Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
  • Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal Pglycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-153.
  • Gong IY, Crown N, Suen CM, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J. 2012;33:2856-2464a.
  • Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-116.
  • Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.